This website uses cookies to ensure you get the best experience on our website.

We and selected partners use cookies or similar technologies to ensure you get the best experience on the Teamtailor website. With respect to cookies that are not considered necessary (as specified in the Cookie Policy), we and our selected partners may use cookies for the following purposes: personalized website experience, develop and improve products and in some cases targeted advertisement that are based on your interests. You can manage or disable cookies by clicking on "Manage cookies" at the bottom of each website page.

Select which cookies you accept

When you visit this website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the website work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Below is a list of different categories of cookies that may be set and that you can freely change. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

These cookies are required and must be accepted to use this site.

Vendors Teamtailor

These cookies collect data about how visitors use this website.

Vendors Google

These cookies allow the website to remember choices you make and provide enhanced, more personal features.

These cookies are used to deliver adverts more relevant to you and your interests.

Calliditas Therapeutics logotype

Welcome to our career site

Connect
Job openings

About Calliditas

 

Calliditas is a commercial-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. We have our headquarters in Stockholm, Sweden and offices in USA, Switzerland and France.

Calliditas’ lead product, TarpeyoTM, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments.

As of December 15th 2021, the FDA has approved the commercialization of Nefecon (TARPEYOTM) in the United States thus making it the first and only FDA-approved treatment. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.

 

 

Our Vision

Addressing niche indications with high unmet medical needs, leveraging agile and cost-effective development and
commercialisation approaches, with the goal to deliver quality oriented and impactful solutions to patients in a timely fashion.


Our Mission

To effectively leverage internal cross competencies in a patient / disease centric manner, to address sustainable market opportunities in a cost-efficient manner thereby delivering quality oriented and impactful solutions to patients and creating value for all our stake holders.

Our Value Words

Expertise

Integrity

Agility

Pioneer

Current job openings

All jobs
Connect with us!